EpicentRx, Inc.

Quick facts

Phase 3 pipeline

• Cisplatin/carboplatin plus etoposide · Oncology
  This combination uses platinum-based chemotherapy agents (cisplatin or carboplatin) to cross-link DNA, combined with etoposide, a topoisomerase II inhibitor that prevents DNA unwinding and repair.
• RRx-001 + eLOOP Device · Oncology
  RRx-001 is a small-molecule immunotherapeutic that works synergistically with the eLOOP device to enhance immune activation and tumor cell death through modulation of immune checkpoints and metabolic pathways.

Phase 2 pipeline

• AdAPT-001
• RRx-001

Phase 1 pipeline

• TMZ Maintenance

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• EpicentRx, Inc. portfolio CI brief
• EpicentRx, Inc. pipeline updates RSS